表观遗传学：技术与全球市场

全球表观遗传学研究工具和试剂、IVD 和治疗市场规模预计将从 2024 年的 48 亿美元成长到 2029年终的 85 亿美元，预测期内的复合年增长率为 11.8%。

基于表观遗传生物标记的 IVD 领域预计将从 2024 年的 19 亿美元增长到 2029年终的44 亿美元，复合年增长率为 18.0%。表观遗传学研究工具和试剂部分预计将从 2024 年的 18 亿美元成长到 2029年终的22 亿美元，复合年增长率为 4.1%。

本报告调查了全球表观遗传学市场，并提供了市场概况的摘要、市场影响因素和市场机会的分析、法律制度、新兴技术和技术发展的趋势、市场规模的趋势和预测、各个细分市场和地区的详细分析、竞争格局以及主要企业的概况。

目录

第一章执行摘要

• 市场展望
• 研究范围
• 市场摘要

第二章 市场概况

• 表观遗传学概述
• DNA甲基化
• 组蛋白修饰
• RNA修饰
• 表观遗传调变器

第三章 市场动态

• 市场动态：概览
• 市场驱动因素
• 癌症发生率上升和肿瘤学领域未满足的需求
• 分析技术和工具的进步
• 增加对生物医学研究的投资
• 精准医疗的趋势
• 人们对液态生物检体的兴趣日益浓厚
• 市场限制
• 从实验室到临床：表观遗传学中的转化差距
• 表观遗传治疗：固态肿瘤临床成功率有限
• 监理环境严峻
• 市场趋势
• 将表观遗传修饰剂与其他治疗层级结合
• 多组体学整合
• 用于表观遗传学研究的长读测序
• 基于表观遗传生物标记的癌症筛检血液检测

第四章 新兴科技与发展

• 新兴技术
• 表观基因编辑
• 表观转录组学
• BET 抑制剂
• 脑膜炎球菌抑制剂
• 肿瘤学以外的应用
• 管道分析
• 概述
• 处于第 2 期或更高阶段开发的新型表观遗传药物

第五章市场区隔分析

• 细分市场
• 表观遗传学研究工具和试剂市场（按研究方法）
• 市场概况
• 市场规模及预测
• DNA甲基化
• 组蛋白修饰
• RNA修饰
• 体外诊断 (IVD) 市场（依临床适应症）
• 市场概况
• 市场规模及预测
• 表观遗传治疗市场（依药物类别）
• 市场概况
• 市场规模及预测
• 地理分布
• 表观遗传学研究工具和试剂市场（按地区）
• 市场规模及预测
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第六章 竞争讯息

• 研究工具和试剂
• 体外诊断
• 治疗

第 7 章表观遗传学市场的永续性：ESG 视角

• ESG：简介
• 表观遗传药物和诊断市场的关键 ESG 问题
• 製药製造业的永续性实践
• 永续包装
• 表观遗传学研究工具市场中的关键 ESG 议题
• ESG 风险评估评分 – 理解资料
• 结论

第 8 章 附录

• 调查方法
• 来源
• 简称
• 公司简介
• ACTIVE MOTIF INC.
• BIO-RAD LABORATORIES INC.
• BIO-TECHNE
• BRISTOL-MYERS SQUIBB CO.
• DAIICHI SANKYO CO. LTD.
• EXACT SCIENCES CORP.
• GUARDANT HEALTH
• HOLOGIC INC.
• LES LABORATOIRES SERVIER
• MERCK KGAA
• NUCLEIX
• PROMEGA CORP.
• QIAGEN
• REVVITY INC. (PERKINELMER)
• THERMO FISHER SCIENTIFIC INC.

The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029.

The global market for epigenetic biomarker-based IVDs is expected to grow from $1.9 billion in 2024 to $4.4 billion by the end of 2029, at a CAGR of 18.0% from 2024 through 2029.

The global market for epigenetics research tools and reagents is expected to grow from $1.8 billion in 2024 to $2.2 billion by the end of 2029, at a CAGR of 4.1% from 2024 through 2029.

Report Scope

This report comprehensively analyzes the global market for epigenetics products, research tools and reagents, epigenetic biomarker-based in vitro diagnostics (IVDs) and epigenetics-targeted therapeutics. It offers both quantitative and qualitative insights to help readers formulate growth strategies, evaluate the market landscape, assess their competitive positions and make informed business decisions regarding epigenetics products and services. The scope of epigenetics-targeted therapeutics includes DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, isocitrate dehydrogenase (IDH) inhibitors and zeste homolog 2 (EZH2) inhibitors.

In this report, BCC Research estimated market data for 2023 (base year) and forecasts values for 2024 through 2029. The research tools and reagents market segmentation is based on the study methods. Epigenetic biomarker-based IVDs market segmentation is based on clinical indications. Epigenetics targeted therapeutics market segmentation is based on drug class. This report also provides regional analyses for epigenetics products.

This report analyzes industry growth drivers, restraints, trends and opportunities in the epigenetics market. The report also covers the competitive landscape and latest trends in epigenetics products. Emerging technologies that impact the epigenetics market are also discussed, along with current information about new products, acquisitions and collaborations related to the epigenetics market.

Report Includes

• 25 data tables and 66 additional tables
• Analyses of the trends in global markets for epigenetics technologies, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
• Estimates of the size and growth forecasts of the global epigenomics market, and a corresponding market share analysis by product type, study method, clinical indication, drug class and region
• Facts and figures pertaining to the market dynamics, technological advancements, regulatory landscape, and the impact of macroeconomic factors
• Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• Evaluation of recent patent activity and key granted and published patents in the industry
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Profiles of leading companies, including Bristol-Myers Squibb Co., Les Laboratoires Servier, Exact Sciences Corp., Thermo Fisher Scientific Inc., and Qiagen

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Epigenetics Overview
• DNA Methylation
• Histone Modification
• RNA Modifications
• Epigenetic Modulators

Chapter 3 Market Dynamics

• Market Dynamics Snapshot
• Market Drivers
• Rising Prevalence of Cancer and Unmet Need in Oncology
• Advances in Analytical Technologies and Tools
• Increasing Investment in Biomedical Research
• Trend Towards Precision Medicine
• Growing Interest in Liquid Biopsy
• Market Restraints
• From Bench to Bedside: The Translation Gap in Epigenetics
• Epigenetic Therapeutics: Limited Clinical Success Against Solid Tumors
• Stringent Regulatory Landscape
• Market Trends
• Combining Epigenetic Modifiers with Other Therapeutic Class
• Multi-omics Integration
• Long-Read Sequencing in Epigenetic Research
• Epigenetic Biomarkers-based Blood Test for Cancer Screening

Chapter 4 Emerging Technologies and Developments

• Emerging Technologies
• Epigenome Editing
• Epitranscriptomics
• Bromodomain and Extra-Terminal Domain Inhibitors
• Menin Inhibitors
• Application Beyond Oncology
• Pipeline Analysis
• Overview
• Novel Epigenetic Therapeutics in Development in Phase 2 and Above

Chapter 5 Market Segmentation Analysis

• Segmentation Breakdown
• Epigenetics Research Tools and Reagents Market, by Study Method
• Market Overview
• Market Size and Forecast
• DNA Methylation
• Histone Modification
• RNA Modification
• In Vitro Diagnostics (IVDs) Market, by Clinical Indication
• Market Overview
• Market Size and Forecast
• Epigenetic Therapeutics Market, by Drug Class
• Market Overview
• Market Size and Forecast
• Geographic Breakdown
• Epigenetics Research Tools and Reagents Market, by Region
• Market Size and Forecast
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 6 Competitive Intelligence

• Research Tools and Reagents
• In Vitro Diagnostics
• Therapeutics

Chapter 7 Sustainability in the Epigenetics Market: An ESG Perspective

• Introduction to ESG
• Key ESG Issues in Epigenetics Pharmaceuticals and Diagnostics Market
• Sustainability Practices in Pharmaceuticals Manufacturing
• Sustainable Packaging
• Key ESG Issues in Epigenetics Research Tools Market
• ESG Risk Ratings Score -- Understanding the Data
• Concluding Remarks

Chapter 8 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ACTIVE MOTIF INC.
• BIO-RAD LABORATORIES INC.
• BIO-TECHNE
• BRISTOL-MYERS SQUIBB CO.
• DAIICHI SANKYO CO. LTD.
• EXACT SCIENCES CORP.
• GUARDANT HEALTH
• HOLOGIC INC.
• LES LABORATOIRES SERVIER
• MERCK KGAA
• NUCLEIX
• PROMEGA CORP.
• QIAGEN
• REVVITY INC. (PERKINELMER)
• THERMO FISHER SCIENTIFIC INC.

List of Tables

• Summary Table : Global Market for Epigenetics Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
• Table 1 : Techniques, Advantages and Disadvantages of Common DNA Methylation Analysis Methods
• Table 2 : Types of Noncoding (ncRNAs)
• Table 3 : Key Programs/Consortiums to Support Epigenetic Research
• Table 4 : Epigenetic Biomarker-based Blood Tests Currently Under Clinical Development
• Table 5 : Companies Developing Products Based on Epigenome Editing Platforms
• Table 6 : BET Inhibitors in Late-Stage Clinical Trials
• Table 7 : Menin Inhibitors in Clinical Trials
• Table 8 : Novel Epigenetic Therapeutic Candidates in Clinical Trials Phase 2 and Above
• Table 9 : Global Market for Epigenetics Research Tools and Reagents, by Study Method, Through 2029
• Table 10 : Commercially Available Epigenetic Biomarker-based IVDs for Colorectal Cancer
• Table 11 : Commercially Available Epigenetic Biomarker-based IVDs for Bladder Cancer
• Table 12 : Commercially Available Epigenetic Biomarker-based IVDs for Cervical Cancer
• Table 13 : Commercially Available Epigenetic Biomarker-based IVDs for Other Indications
• Table 14 : FDA Breakthrough Device Designated Epigenetic Biomarker-based Clinical Assays Currently Undergoing Clinical Validation
• Table 15 : Global Market for Epigenetic Biomarker-based IVDs, by Clinical Indication, Through 2029
• Table 16 : Commercially Available DNMT Inhibitors
• Table 17 : Commercially Available HDAC Inhibitors
• Table 18 : Commercially Available IDH Inhibitors
• Table 19 : Commercially Available EZH2 Inhibitors
• Table 20 : Global Market for Epigenetic Therapeutics, by Drug Class, Through 2029
• Table 21 : Global Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Region, Through 2029
• Table 22 : North American Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
• Table 23 : North American Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029
• Table 24 : European Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
• Table 25 : European Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029
• Table 26 : Asia-Pacific Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
• Table 27 : Asia-Pacific Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029
• Table 28 : RoW Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
• Table 29 : Global Market Shares of Epigenetic Biomarkers-based IVDs, by Company, 2023
• Table 30 : Commercially Available Epigenetics-Targeted Drugs
• Table 31 : Key Sustainability Practices in the Pharmaceuticals Industry
• Table 32 : ESG Risk Ratings of Key Companies in the Epigenetics Market, 2024
• Table 33 : Ethos Impact Inc. Score Card for Key Companies in the Epigenetics Market, 2024
• Table 34 : Information Sources for this Report
• Table 35 : Abbreviations Used in the Report
• Table 36 : Active Motif Inc.: Company Snapshot
• Table 37 : Active Motif Inc.: Product Portfolio
• Table 38 : Active Motif Inc.: News/Key Developments, 2022
• Table 39 : Bio-Rad Laboratories Inc.: Company Snapshot
• Table 40 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
• Table 41 : Bio-Rad Laboratories Inc.: Product Portfolio
• Table 42 : Bio-Rad Laboratories Inc.: News/Key Developments, 2023 and 2024
• Table 43 : Bio-Techne: Company Snapshot
• Table 44 : Bio-Techne: Financial Performance, FY 2022 and 2023
• Table 45 : Bio-Techne: Product Portfolio
• Table 46 : Bio-Techne: News/Key Developments, 2023
• Table 47 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 48 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
• Table 49 : Bristol-Myers Squibb Co: Product Portfolio
• Table 50 : Daiichi Sankyo Co. Ltd.: Company Snapshot
• Table 51 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 52 : Daiichi Sankyo Co. Ltd.: Product Portfolio
• Table 53 : Daiichi Sankyo Co. Ltd.: News/Key Developments, 2022-2024
• Table 54 : Exact Sciences Corp.: Company Snapshot
• Table 55 : Exact Sciences Corp.: Financial Performance, FY 2022 and 2023
• Table 56 : Exact Sciences Corp.: Product Portfolio
• Table 57 : Exact Sciences Corp.: News/Key Developments, 2023 and 2024
• Table 58 : Guardant Health: Company Snapshot
• Table 59 : Guardant Health: Financial Performance, FY 2022 and 2023
• Table 60 : Guardant Health: Product Portfolio
• Table 61 : Guardant Health: News/Key Developments, 2023 and 2024
• Table 62 : Hologic Inc.: Company Snapshot
• Table 63 : Hologic Inc.: Financial Performance, FY 2023 and 2024
• Table 64 : Hologic Inc.: Product Portfolio
• Table 65 : Les Laboratoires Servier: Company Snapshot
• Table 66 : Les Laboratoires Servier: Financial Performance, FY 2022 and 2023
• Table 67 : Les Laboratoires Servier: Product Portfolio
• Table 68 : Les Laboratoires Servier: News/Key Developments, 2023 and 2024
• Table 69 : Merck KGaA: Company Snapshot
• Table 70 : Merck KGaA: Financial Performance, FY 2022 and 2023
• Table 71 : Merck KGaA: Product Portfolio
• Table 72 : Merck KGaA: News/Key Developments, 2023 and 2024
• Table 73 : Nucleix: Company Snapshot
• Table 74 : Nucleix: Product Portfolio
• Table 75 : Nucleix: News/Key Developments, 2023 and 2024
• Table 76 : Promega Corp.: Company Snapshot
• Table 77 : Promega Corp.: Product Portfolio
• Table 78 : Promega Corp.: News/Key Developments, 2023
• Table 79 : Qiagen: Company Snapshot
• Table 80 : Qiagen: Financial Performance, FY 2022 and 2023
• Table 81 : Qiagen: Product Portfolio
• Table 82 : Qiagen: News/Key Developments, 2023 and 2024
• Table 83 : Revvity Inc. (PerkinElmer): Company Snapshot
• Table 84 : Revvity Inc. (PerkinElmer): Financial Performance, FY 2022 and 2023
• Table 85 : Revvity Inc. (PerkinElmer): Product Portfolio
• Table 86 : Revvity Inc. (PerkinElmer): News/Key Developments, 2023
• Table 87 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 88 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
• Table 89 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 90 : Thermo Fisher Scientific Inc.: News/Key Developments, 2024

List of Figures

• Summary Figure : Global Market Shares of Epigenetics Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
• Figure 1 : Market Dynamics of Epigenetics
• Figure 2 : Estimated New Cancer Cases Globally, 2022, 2045 and 2050
• Figure 3 : Global Blood Cancer Incidence, by Cancer Type, 2022 vs. 2045
• Figure 4 : PubMed Article Count: "Epigenetic," 2018-2024
• Figure 5 : Overcoming Barriers in the Clinical Application of Epigenetics
• Figure 6 : PubMed Article Count: "Epitranscriptomic" and "RNA Modification," 2021-2024
• Figure 7 : Trends in Clinical Trials for Epigenetic Therapeutic Agents, by Drug Class, as of December 2024
• Figure 8 : Global Market Shares of Epigenetics Research Tools and Reagents, by Study Method, 2023
• Figure 9 : Global Market Shares of Epigenetic Biomarker-based IVDs, by Clinical Indication, 2023
• Figure 10 : Global Market Shares of Epigenetic Therapeutics, by Drug Class, 2023
• Figure 11 : Global Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Region, 2023
• Figure 12 : North American Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
• Figure 13 : North American Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023
• Figure 14 : European Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
• Figure 15 : European Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023
• Figure 16 : Worldwide Incidence of Blood Cancer Cases, by Region, 2022
• Figure 17 : Asia-Pacific Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
• Figure 18 : Asia-Pacific Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023
• Figure 19 : RoW Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
• Figure 20 : Principle Competitive Factors in Epigenetics Research Tools Market
• Figure 21 : Global Market Shares of Leading Manufacturers of Epigenetics-Targeted Therapeutics, 2023
• Figure 22 : Selected Factors Driving ESG
• Figure 23 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 24 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 25 : Bio-Techne: Revenue Share, by Business Unit, FY 2023
• Figure 26 : Bio-Techne: Revenue Share, by Country/Region, FY 2023
• Figure 27 : Bristol-Myers Squibb Co: Revenue Share, by Business Unit, FY 2023
• Figure 28 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
• Figure 29 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 30 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 31 : Exact Sciences Corp.: Revenue Share, by Business Unit, FY 2023
• Figure 32 : Exact Sciences Corp.: Revenue Share, by Country/Region, FY 2023
• Figure 33 : Guardant Health: Revenue Share, by Business Unit, FY 2023
• Figure 34 : Guardant Health: Revenue Share, by Country/Region, FY 2023
• Figure 35 : Hologic Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 36 : Hologic Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 37 : Les Laboratoires Servier: Revenue Share, by Business Unit, FY 2023
• Figure 38 : Les Laboratoires Servier: Revenue Share, by Region, FY 2023
• Figure 39 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
• Figure 40 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
• Figure 41 : Qiagen: Revenue Share, by Business Unit, FY 2023
• Figure 42 : Qiagen: Revenue Share, by Country/Region, FY 2023
• Figure 43 : Revvity Inc. (PerkinElmer): Revenue Share, by Business Unit, FY 2023
• Figure 44 : Revvity Inc. (PerkinElmer): Revenue Share, by Country/Region, FY 2023
• Figure 45 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023
• Figure 46 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023